{"id":"NCT01862874","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)","officialTitle":"A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-27","primaryCompletion":"2017-08-30","completion":"2017-08-30","firstPosted":"2013-05-27","resultsPosted":"2018-08-31","lastUpdate":"2019-04-02"},"enrollment":1124,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Anogenital Human Papilloma Virus Infection","Condyloma Acuminata"],"interventions":[{"type":"BIOLOGICAL","name":"V501","otherNames":["GARDASIL™","Quadrivalent HPV (Type 6, 11, 16 and 18) L1 Virus-Like Particle vaccine"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"V501","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to evaluate the efficacy and tolerability of V501 (quadrivalent Human Papilloma Virus \\[HPV\\] \\[Type 6, 11, 16 and 18\\] L1 Virus-Like Particle vaccine, GARDASIL™) in healthy, 16- to 26-year old Japanese males. The hypotheses tested are: 1) V501 reduces the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection compared with placebo, and 2) V501 reduces the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, condyloma acuminata, penile/perianal/perineal intraepithelial neoplasia, or penile, perianal, or perineal cancer compared with placebo.","primaryOutcome":{"measure":"Combined Incidence of HPV Type 6, 11, 16, or 18-related Persistent Infection","timeFrame":"Up to Month 36","effectByArm":[{"arm":"V501","deltaMin":0.3,"sd":null},{"arm":"Placebo","deltaMin":1.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"16 Years","sex":"MALE","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["30797638"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":554},"commonTop":["Injection-site pain","Injection-site erythema","Injection-site swelling"]}}